evipedia.ai
← Back

Olive Leaf Extract for Health & Longevity

Evidence Review created on 10/12/2026 using AI4L / Opus 5.5

Also known as: Olea europaea Leaf Extract, OLE, Olive Leaf, Oleae folium, Oleuropein-Rich Olive Leaf Extract, EFLA 943, Bonolive, Atherolive

Motivation

Olive leaf extract is a concentrated preparation made from the leaves of the olive tree (Olea europaea), not from the fruit or its oil. Its main active ingredient is a bitter plant compound that the body converts into substances also found in high-quality extra virgin olive oil. It draws interest because it offers a concentrated, oral source of the plant compounds thought to contribute to the reputation of traditional Mediterranean eating.

Olive leaves have been brewed as a folk remedy around the Mediterranean for centuries, and the extract became a widely sold dietary supplement in the 1990s. Clinical researchers have since studied it mainly for blood pressure and blood sugar, while laboratory work on its main compound has drawn the attention of scientists who study muscle and cellular aging.

This review examines the human, animal and laboratory evidence on olive leaf extract as an ongoing supplement for health-focused adults. It covers the expected benefits, the risks and interactions, how the extract is dosed and sourced, and how strong and how independent the underlying research is.

Benefits - Risks - Protocol - Conclusion

Five accessible expert and academic sources that discuss olive leaf extract or its main compound in depth.

No directly relevant content on olive leaf extract was found from Peter Attia or Andrew Huberman in web and on-site searches. Chris Kresser mentions olive leaf only in a short paragraph within a list of cold and flu remedies, which does not discuss it in enough depth to qualify.

Grokipedia

Olive leaf

A broad encyclopedic overview of olive leaf botany, oleuropein chemistry, traditional uses, commercial extracts and clinical evidence; useful background, though it applies no independent evidence grading.

Examine

Olive Leaf Extract

Evidence-graded summary placing blood pressure among its best-supported outcomes and listing 500–1,000 mg daily as the studied range, with oleuropein commonly standardized at 5–20%.

ConsumerLab

Olive Leaf Extract Supplements Review

Independent product testing found oleuropein per serving varied about 3-fold across brands; approved products met label claims and passed heavy-metal screening, and full results require membership.

Systematic Reviews

The five most relevant pooled analyses of randomized human trials of olive leaf extract, spanning positive and null conclusions.

No systematic review of adverse effects was found; risks are represented only by safety outcomes within these efficacy reviews.

Mechanism of Action

Olive leaf extract’s activity is attributed mainly to oleuropein, a secoiridoid (a class of bitter plant compounds) making up as much as 6–9% of dry leaf weight (review by El & Karakaya, 2009). In the gut and liver, oleuropein is split into hydroxytyrosol, which sulfotransferase and glucuronosyltransferase enzymes convert into conjugates (water-soluble tags added before excretion); COMT (catechol-O-methyltransferase, which adds methyl groups) inactivates part of it.

  • Blood vessels: laboratory and animal studies suggest antioxidant, anti-inflammatory and cardioprotective actions (review by Nediani et al., 2019), proposed to relax vessels and limit oxidation of LDL (low-density lipoprotein, the main cholesterol carrier linked to artery disease).
  • Sugar handling: oleuropein inhibits sucrase (the gut enzyme that splits table sugar) and intestinal glucose transport, blunting the blood-sugar rise after a small sucrose load but not after bread (Kerimi et al., 2019, with a BioActor co-author).
  • Cellular energy: in mice, oleuropein activates the MCU (mitochondrial calcium uniporter, the mitochondrial calcium channel), which switches on PDH (pyruvate dehydrogenase, an enzyme that feeds carbohydrate fuel into mitochondria) (Gherardi et al., 2025, with Nestlé co-authors).
  • Competing view: the popular antioxidant explanation is contested; supplementation did not change urinary oxidative-damage markers in healthy adults (Kendall et al., 2009).

Pharmacology: hydroxytyrosol metabolites peak about 1–1.5 hours after ingestion and are excreted in urine within 8 hours, implying a short, unreported half-life (de Bock et al., 2013). No selectivity or human tissue-distribution data exist; in mice, oleuropein induced CYP (cytochrome P450, the liver’s main drug-processing) enzymes (Malliou et al., 2021).

Historical Context & Evolution

Olive leaves were used in traditional remedies in Greece, Spain, Italy, France, Turkey, Israel, Morocco and Tunisia, taken as tea, powder or extract (review by El & Karakaya, 2009). The original intended use was folk treatment of fevers, infections, high blood pressure and diabetes, not health optimization.

In 1969, laboratory researchers reported that calcium elenolate, derived from an olive-leaf compound, inhibited viruses in cell culture (Renis, 1969). From the 1990s, olive leaf extract was sold as a supplement, largely on antimicrobial and immune claims.

Interest shifted to cardiometabolic health after trials from 2008 onward reported lower blood pressure and cholesterol (Perrinjaquet-Moccetti et al., 2008, Frutarom-run) and better insulin sensitivity (how effectively insulin lowers blood sugar) (de Bock et al., 2013, Comvita co-funded), several of them run with extract manufacturers. In 2017–2018 the European Medicines Agency’s herbal committee accepted olive leaf only as a traditional remedy for mild water retention, noting insufficient clinical-trial evidence (EMA).

The current picture is unsettled rather than final. Newer trials and a 2026 pooled analysis found no lipid or blood-sugar effects, while a large 2025 trial (with a co-author from extract maker Belpharma) and earlier pooled analyses support a modest blood-pressure effect. What changed most recently is the framing: mouse research (Gherardi et al., 2025) showing that oleuropein activates muscle mitochondrial calcium uptake, which declines with age, has recast the extract as a candidate healthspan (years lived in good health) compound, with human aging-related trials only beginning.

Expected Benefits

High 🟩 🟩 🟩

Lower Blood Pressure ⚠️ Conflicted

The extract modestly lowers blood pressure, possibly by relaxing blood vessels, most clearly in prehypertension (pressure just above normal) or mild hypertension. Two groups’ placebo-controlled trials agree: Lockyer (Reading and Auckland; half-funded by Comvita) and Lamti (Monastir; 621 treated patients; Belpharma co-author), plus a captopril-comparison (standard blood-pressure drug) trial by Susalit, co-authored by Frutarom. Stevens (BioActor-affiliated) and de Bock (Comvita co-funded) found no change in adults not selected for raised pressure, and Lauwers none with raised pressure, using leaf-plus-fruit extract. Net reading: a small, inconsistently reproduced reduction with raised pressure.

Magnitude: Systolic blood pressure 3.86 mmHg lower than control, 95% CI (confidence interval, the range likely to contain the true effect) −6.44 to −1.28, pooled from the blood-pressure trials of a 12-study meta-analysis (Razmpoosh et al., 2022); 24-hour systolic pressure 3.33 mmHg lower than control in Lockyer et al., 2017 (CI not reported).

Medium 🟩 🟩

Shorter Respiratory Illness

In a nine-week trial of 32 adolescent athletes in Auckland, New Zealand (Somerville), olive leaf extract supplying 100 mg oleuropein daily did not change how often upper respiratory illness (colds and similar infections) occurred but shortened how long it lasted. Proposed mechanisms are antiviral and anti-inflammatory actions of oleuropein and hydroxytyrosol. This is one small trial in young people, without replication in adults.

Magnitude: Sick days odds ratio (relative odds versus placebo) 0.72, 95% CI 0.56 to 0.93, with mean episode duration 9.7 versus 12.3 days; illness incidence odds ratio 1.02, 95% CI 0.21 to 4.44, meaning no difference (Somerville et al., 2019).

Better Menopausal Quality of Life

In Imperatrice (60 postmenopausal women, 250 mg daily for 12 weeks, conducted with BioActor), the overall MENQoL (Menopause-Specific Quality of Life questionnaire) score improved versus placebo, while hot-flash interference and the individual symptom domains did not change. The mechanism is unclear; vascular and anti-inflammatory actions are proposed. This is a single industry-run trial with a small effect.

Magnitude: Overall MENQoL score 0.2 points better than placebo (statistically significant; the 95% CI is printed ambiguously in the source), with hot-flash interference unchanged (Imperatrice et al., 2024).

Faster Recovery from Hospitalized COVID-19 ⭕️ Not Central to Health & Longevity

In a triple-blinded (patients, clinicians and analysts unaware of assignment) trial of 150 hospitalized COVID-19 patients in Iran (Ahmadpour), 250 or 500 mg olive leaf extract twice daily for five days improved temperature, breathing rate, oxygen levels and CRP (C-reactive protein, a blood inflammation marker) versus placebo. It bears on treatment of acute infection rather than long-term health. Replication is lacking.

Magnitude: On day 5, the 250 mg arm had body temperature 0.34 °C lower, respiratory rate 1.66 breaths per minute lower and oxygen saturation 1.81 percentage points higher than placebo (CI not reported) (Ahmadpour et al., 2023).

Low 🟩

Preserved Bone Density After Menopause ⚠️ Conflicted

Filip (BioActor-run, 12 months, 64 women with osteopenia (bone density below normal)) found stable spine BMD (bone mineral density) versus decline on calcium alone, but gave extract only with calcium. Imperatrice (also BioActor-run; 12 weeks, extract alone) found no difference except the right arm. Net reading: possible, unreplicated spine effect.

Magnitude: Right-arm BMD 0.017 higher than placebo, 95% CI 0.003 to 0.030, after 12 weeks, with no difference at other sites (Imperatrice et al., 2024).

Better Gum Healing as an Add-On to Periodontal Treatment

Forbes-Hernández gave 60 older adults with periodontitis (chronic gum infection that destroys tooth support) a 40% oleuropein extract or placebo for 120 days alongside deep cleaning. Pocket depth and gum attachment improved more with the extract. Evidence is indirect: one trial, extract tested only as an add-on.

Magnitude: Greater reduction in probing pocket depth and greater gain in clinical attachment level than placebo across multiple tooth categories after 120 days; the published abstract reports these as statistically significant differences without a pooled outcome figure (Forbes-Hernández et al., 2026).

Better Blood Sugar Control ⚠️ Conflicted

De Bock (Auckland) found better insulin sensitivity in overweight men; Wainstein (Israel) found lower HbA1c (three-month average blood sugar) in type 2 diabetes. ESOLED found no HbA1c effect, and pooled trials showed no glucose benefit. Net reading: a reliable blood-sugar benefit is not established.

Magnitude: Insulin sensitivity (Matsuda index) 15% higher than placebo, 5.46 versus 4.73 (CI for the difference not reported), in de Bock et al., 2013; no HbA1c difference from placebo over 24 weeks in Leach & Breakspear, 2025.

Modest Improvement in Blood Lipids ⚠️ Conflicted

Lockyer and Pinckaers (Nestlé co-authors) found lower LDL; Stevens, with lipids as primary outcome, found none. Pooled analyses split: Mansouri found reductions, Câmara Rocha Menezes none. Net reading: any lipid benefit is small and not reliably reproduced.

Magnitude: LDL cholesterol 0.19 mmol/L and triglycerides 0.18 mmol/L lower than control after 6 weeks (CI not reported) in Lockyer et al., 2017; triglycerides 9.51 mg/dL lower, 95% CI −17.83 to −1.18, pooled in Razmpoosh et al., 2022.

Greater Weight Loss During Calorie Restriction ⚠️ Conflicted

With a reduced-calorie diet, Haidari (Ahvaz, Iran) found greater weight and fat loss in women with obesity. Without dieting, Stevens and de Bock found no weight change, while Lamti reported lower body weight and a pooled analysis found a reduction. Net reading: any weight effect is small and inconsistent.

Magnitude: Body weight fell 4.1 kg with the extract versus 2.8 kg with placebo over 8 weeks, and fat mass 2.6 versus 1.3 kg (between-group differences significant, CI not reported) (Haidari et al., 2021).

Knee Joint Comfort ⚠️ Conflicted

Horcajada (124 adults, Bonolive, Nestlé-conducted) found no overall effect on knee function after six months; only a post hoc (unplanned, after-the-fact) high-pain subgroup improved. Roshani reported less pain in older adults with knee osteoarthritis (joint wear) without a placebo arm. Net reading: no reliable joint benefit is shown.

Magnitude: Global KOOS (Knee injury and Osteoarthritis Outcome Score) 3.79 points higher than placebo at 6 months, 95% CI −2.77 to 10.35 (not significant), with improvement confined to the post hoc high-pain subgroup (Horcajada et al., 2022).

Faster Cold Sore Healing with Topical Use ⭕️ Not Central to Health & Longevity

Topical olive leaf preparations healed herpes labialis (cold sores) at least as fast as acyclovir (an antiviral) cream in two small trials (Toulabi, Iran; Gaizeh Al-Hallak, Syria). The evidence is indirect: skin application, not the oral extract. It bears on cold-sore treatment, not long-term health.

Magnitude: Lesion crusts fell off on mean day 4.05 versus 4.85 with acyclovir cream (statistically significant), while time to pain relief did not differ (Gaizeh Al-Hallak et al., 2024).

Brain Protection

The GOLDEN trial gave 55 adults with mild Alzheimer’s disease olive leaf beverage plus Mediterranean diet advice; MMSE (a standard memory test) scores held steadier than with advice alone. An oleuropein derivative reduced amyloid plaques (Alzheimer’s protein clumps) in mice (Pantano). Evidence is indirect: leaf beverage, not extract, without placebo.

Magnitude: After 6 months, mean MMSE change was close to 0 with the olive leaf beverage versus −4.1 points with diet advice alone (between-group difference significant, CI not reported) (Loukou et al., 2024).

Muscle Energy and Performance ⚠️ Conflicted

Oleuropein improved endurance in aged mice (Gherardi). In 40 older men, Pinckaers found higher muscle PDH activity but no strength or fatigue change; in young men, Lanfranchi found better power only in the first sprint (both with Nestlé co-authors). Net reading: no reliable functional benefit shown.

Magnitude: Leg strength and fatigue resistance did not differ from placebo after 29 days, while fractional muscle PDH activity was 49% versus 38% with placebo after 36 days (Pinckaers et al., 2025).

Antimicrobial Activity ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Olive leaf compounds inhibit viruses and Candida yeast in cultures (Renis; Zorić). Added to antifungal drugs, the extract did not further lower oral Candida counts (Kinkela Devčić); this is indirect add-on evidence bearing on infection treatment, not long-term health. Net reading: no human infection-clearance effect.

Magnitude: Oral Candida colony counts did not differ between extract-plus-antifungal and antifungal-alone groups; the literature reports only p-values (the probability of seeing such a result by chance alone), no outcome figure (Kinkela Devčić et al., 2025).

Speculative 🟨

Slowing Cellular Aging

Oleuropein activated muscle mitochondrial calcium uptake, which declines with age, in mice (Gherardi) and acts on several aging hallmarks in laboratory models (a review by Calabrò). The basis is animal and mechanistic only.

Skin Aging

In Lasfar (65 postmenopausal women, authors from ingredient firm Solabia), extract users had fewer skin pores than placebo in an exploratory subgroup. Blood tissue-aging markers did not change significantly. Neither is a proven health predictor.

Lower Inflammation ⚠️ Conflicted

Javadi reported lower IL-6 and IL-8 (inflammatory signaling proteins), but de Bock found IL-6 rose and a pooled analysis found no change. These markers are unvalidated. Net reading: no consistent anti-inflammatory signal.

Anticancer Activity

Oleuropein showed anticancer effects in laboratory and animal studies summarized in a narrative review (review by Nediani et al., 2019). No human cancer-outcome data exist; the basis is laboratory and animal work only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No genetic variant has been studied. Hydroxytyrosol is partly inactivated by COMT (catechol-O-methyltransferase, an enzyme that adds methyl groups to catechol compounds), so common COMT variants could plausibly alter exposure; this remains untested.
  • Baseline blood pressure: Pooled reductions were larger in people with hypertension than overall (Razmpoosh et al., 2022), while trials in adults not selected for raised blood pressure found no change.
  • Baseline lipids and glucose: Lipid and glucose signals came mainly from people with prediabetes, raised cholesterol or obesity; even there, results conflict, and people with normal values show little measurable change.
  • Sex: Men had about four times the plasma hydroxytyrosol exposure of women at equal doses (de Bock et al., 2013); in one small trial, sick days fell in female but rose in male athletes (Somerville et al., 2019); many trials enrolled one sex only.
  • Pre-existing conditions: Positive trials occurred in prehypertension, mild hypertension, osteopenia, periodontitis and respiratory infection; benefits in metabolically healthy adults are largely untested.
  • Age: Older adults showed enzyme (Pinckaers et al., 2025) or gum-health (Forbes-Hernández et al., 2026) changes but no strength or knee-function gains (Horcajada et al., 2022); adults over 70 are poorly represented.
  • Formulation: Liquid extract produced higher plasma oleuropein peaks than capsules (de Bock et al., 2013), and oleuropein content varies widely between products, which may contribute to inconsistent trial results.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been shown to exceed placebo rates in controlled trials from more than one research group.

Medium 🟥 🟥

No risk reaches Medium: no single controlled trial has shown a statistically tested adverse-event excess over placebo; the remaining harms rest on small untested symptom counts, uncontrolled reports, mechanism or animal data.

Low 🟥

Mild Digestive Upset ⚠️ Conflicted

Stomach upset, headache or acne is reported: four extract users versus one placebo user in Somerville, and during both phases in Lockyer. Stevens found no difference from placebo on a validated digestive-symptom scale. Net reading: digestive complaints are uncommon, mild and not clearly extract-related.

Magnitude: In Somerville et al., 2019, 3 extract users reported stomach aches and headaches and 1 acne, versus 1 placebo user with stomach aches (no statistical comparison reported); in Lockyer et al., 2017, 4 of 60 participants reported mild stomach upset and 1 acne, with the same symptoms also occurring during the control phase (arm-specific rates not reported); Gastrointestinal Symptom Rating Scale scores did not differ from placebo in Stevens et al., 2021.

Allergic Reaction in People Sensitized to Olive Pollen

Olive tree pollen is a major seasonal allergen, and ConsumerLab cautions that people allergic to olive or related pollens may react to the extract. In Stevens, one participant withdrew because of a suspected olive allergy. Evidence is a single uncontrolled report.

Magnitude: 1 of 77 participants withdrew for a suspected olive allergy in Stevens et al., 2021; the treatment arm was not reported, so no comparison with placebo is possible.

Excessive Blood Pressure Lowering with Antihypertensive Drugs ⚠️ Conflicted

Because the extract lowers blood pressure, combining it with antihypertensive (blood-pressure-lowering) drugs could cause dizziness. However, Lamti randomized 621 patients already on such drugs (307 to the extract) and reported no significant adverse events. Net reading: excessive lowering is plausible but not observed.

Magnitude: Not quantified in available studies. No trial has reported a rate of symptomatic low blood pressure, and the 621-patient trial reported no significant adverse events (Lamti et al., 2025).

Speculative 🟨

Low Blood Sugar with Glucose-Lowering Drugs

Additive glucose lowering could cause hypoglycemia (low blood sugar) in people on diabetes drugs, a caution ConsumerLab flags. No trial has tracked low-blood-sugar episodes; the basis is mechanistic only.

Altered Drug Metabolism

In mice, oleuropein induced several liver CYP enzymes through PPARα (a fat-metabolism control switch), which could speed clearance of some drugs (Malliou). No human study exists; the basis is animal data only.

Increased Bleeding Tendency

Olive leaf polyphenols reduced platelet (blood-clotting cell) clumping in human blood samples in the laboratory (Singh). No bleeding events have been reported; the basis is laboratory data only.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant is known to alter the extract’s risks. Variants in drug-processing enzymes matter only indirectly, for people on narrow-margin drugs whose clearance the extract might affect (theoretical).
  • Baseline blood pressure: People with low or low-normal blood pressure, or prone to dizziness on standing, have less margin for further lowering.
  • Baseline glucose: People on glucose-lowering medication with tightly controlled HbA1c have greater theoretical exposure to hypoglycemia.
  • Sex: No sex difference in adverse events is reported. Women absorbed less hydroxytyrosol than men in one small study (de Bock et al., 2013), which would imply lower, not higher, exposure.
  • Pre-existing conditions: Severe heart or kidney disease requiring reduced fluid intake excludes olive leaf medicines (EMA); olive or related pollen allergy raises allergic risk.
  • Age: Older adults more often take antihypertensive, glucose-lowering and blood-thinning drugs and are more prone to falls from low blood pressure; olive leaf medicines are restricted to adults (EMA).

Key Interactions & Contraindications

No human drug-interaction study of olive leaf extract exists; entries below rest on regulator statements, trial safety data or mechanism.

Prescription drugs

  • Antihypertensive drugs (lisinopril, amlodipine, losartan): Monitor. Additive lowering could cause dizziness or falls; in 621 patients already on such drugs, no significant adverse events were reported (Lamti et al., 2025). Home blood-pressure checks during the first weeks mitigate this.
  • Diuretics (drugs that increase urine output; furosemide, hydrochlorothiazide): Monitor (theoretical). Olive leaf is traditionally used to increase urine output (EMA), so combination could add to fluid and electrolyte loss. Periodic electrolyte checks mitigate this.
  • Glucose-lowering drugs (metformin, glimepiride, insulin): Monitor (theoretical). Additive lowering could cause hypoglycemia. Glucose self-monitoring during the first two weeks mitigates this.
  • Anticoagulants and antiplatelet drugs (blood thinners; warfarin, apixaban, clopidogrel): Caution (theoretical). Laboratory platelet inhibition (Singh et al., 2008) suggests added bleeding risk. INR (international normalized ratio, a clotting-time test) checks for warfarin users mitigate this.
  • Narrow-margin drugs cleared by CYP enzymes (warfarin, tacrolimus, cyclosporine): Caution (theoretical). Oleuropein induced mouse Cyp1a2 and Cyp3a enzymes (Malliou et al., 2021), which could lower drug levels and effect. Drug-level checks after starting or stopping mitigate this.

Over-the-counter medications

  • NSAIDs (non-steroidal anti-inflammatory pain relievers; ibuprofen, naproxen, aspirin): Monitor (theoretical). Combined effects on platelets could increase bruising or gastrointestinal bleeding. Avoiding regular high-dose combined use mitigates this.
  • Decongestants (pseudoephedrine, phenylephrine): Monitor (theoretical). These raise blood pressure and may offset the extract’s lowering effect; no harmful interaction is expected.

Supplements

  • Blood-pressure-lowering supplements (garlic, hibiscus, beetroot nitrate, coenzyme Q10, potassium): Monitor (theoretical, except potassium). Combined lowering could cause dizziness; an olive leaf–potassium product was well tolerated (Fladerer-Grollitsch et al., 2026, maker Apomedica co-authored). Home blood-pressure checks mitigate this.
  • Glucose-lowering supplements (berberine, cinnamon, chromium): Monitor (theoretical). Additive glucose lowering could cause hypoglycemia, mainly in people also taking diabetes drugs. Glucose self-monitoring mitigates this.
  • Antiplatelet supplements (high-dose fish oil, ginkgo, vitamin E): Monitor (theoretical). Additive bleeding tendency could increase bruising. Pausing before surgery mitigates this.

Other interventions

  • Olive-oil-rich diets: None expected. Extra virgin olive oil supplies the same polyphenol family; combined intake raises total exposure without known harm.
  • Fasting or very-low-carbohydrate diets: Monitor (theoretical). In people on diabetes drugs, these may add to glucose lowering and hypoglycemia risk. Glucose self-monitoring mitigates this.

Populations who should avoid Olive Leaf Extract:

  • People with severe heart or kidney disease in whom fluid intake is restricted (EMA)
  • Children and adolescents, as olive leaf medicines are restricted to adults (EMA)
  • Pregnant or breastfeeding women, for whom no safety data exist (theoretical)
  • People with known allergy to olive pollen or related Oleaceae plants such as ash and privet (theoretical)
  • People with symptomatic low blood pressure (theoretical)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Low starting dose: Starting at 250–500 mg daily for 1–2 weeks before moving to trial doses limits digestive upset and reveals individual blood-pressure sensitivity.
  • Taking with meals: Taking each dose with food limits stomach upset, the most commonly reported complaint (Lockyer et al., 2017).
  • Home blood-pressure checks: With antihypertensive drugs, seated morning readings 3–4 times weekly for the first 4 weeks detect excessive lowering; readings below the person’s usual range or dizziness prompt review with the prescriber.
  • Glucose monitoring with diabetes drugs: Daily fingerstick or continuous glucose readings for the first 2 weeks catch hypoglycemia early and allow prescribers to adjust medication.
  • Allergy precaution: For people with olive-pollen hay fever, starting at the lowest dose and stopping at hives, wheezing or swelling limits allergic reactions.
  • Pre-surgery pause: Stopping 1–2 weeks before scheduled surgery or dental extraction limits the theoretical bleeding risk from platelet inhibition.
  • Drug-level checks: For users of warfarin, tacrolimus or cyclosporine, an INR or drug-level check 1–2 weeks after starting or stopping catches altered drug clearance (theoretical).
  • Verified products: Choosing third-party-tested products with stated oleuropein content limits contamination and dose uncertainty; oleuropein per serving varied about 3-fold across products tested by ConsumerLab.

Therapeutic Protocol

Timing, splitting, cycling and dose-increase parameters without a citation reflect common practice.

  • Standard extract dose: 500 mg twice daily of the EFLA 943 extract, the regimen tested against captopril (Susalit et al., 2011); 500–1,000 mg daily is the commonly cited range (Examine supplement page).
  • Oleuropein-based dosing: Daily oleuropein in extract-only trials ranged from 51 mg (de Bock) through 136 mg (Lockyer) to about 200 mg with EFLA 943, per Lockyer’s discussion of earlier trials; 250 mg of 40% extract supplies 100 mg (Pinckaers).
  • Low-dose standardized extract: Bonolive at 250 mg daily (Imperatrice et al., 2024) or 125 mg twice daily (Horcajada et al., 2022), an approach developed by BioActor and tested with Nestlé.
  • Olive leaf tea: 330 mL with each of three daily meals for 12 weeks was the regimen in a Japanese prediabetes trial (Araki et al., 2019); polyphenol content of home-brewed tea is uncontrolled.
  • Integrative antimicrobial use: Chris Kresser cites 500–1,000 mg daily for cold and flu prevention (Kresser), a use resting on laboratory antiviral data rather than prevention trials.
  • Time of day: Morning dosing, or morning and evening dosing, with meals is typical; liquid extracts reach peak blood levels faster than capsules (de Bock et al., 2013).
  • Half-life: Hydroxytyrosol metabolites peak about 1–1.5 hours after ingestion and are cleared in urine within 8 hours (de Bock et al., 2013), indicating short persistence.
  • Single versus split dose: Short persistence favors twice-daily splitting, as in the captopril-comparison trial and the positive blood-pressure trial by Lockyer; the positive glucose trial nonetheless used once-daily dosing (Wainstein).
  • Genetic polymorphisms: No genotype-guided dosing exists; COMT variants are a theoretical modifier of hydroxytyrosol clearance.
  • Sex: Women had lower hydroxytyrosol exposure than men at equal doses (de Bock et al., 2013); no sex-specific dose has been tested.
  • Age: In older adults, 250 mg daily was the trial dose in men around 60 (Pinckaers et al., 2025) and in postmenopausal women aged 47–70 (Imperatrice et al., 2024); no age-specific dose has been tested.
  • Baseline biomarkers: Pooled blood-pressure and triglyceride reductions were larger in adults with hypertension (Razmpoosh et al., 2022); normal baselines leave less room for change.
  • Pre-existing conditions: In diabetes on medication, low blood pressure, or heart or kidney disease requiring fluid restriction (EMA), dose choice depends most on concurrent treatment.
  • Popularizers: Frutarom (EFLA 943) and BioActor (Bonolive) built the trial base, Life Extension markets olive leaf products, and Rhonda Patrick has discussed it (Patrick).

Discontinuation & Cycling

  • Duration: Trial benefits appeared during continuous use lasting 6 weeks to 12 months; blood-pressure effects are presumed to require ongoing intake, so use is open-ended rather than a short course.
  • Withdrawal effects: None have been described in trials or case reports.
  • Tapering: Not required pharmacologically; people on antihypertensive or glucose-lowering drugs may need medication re-checks after stopping, since any additive effect disappears.
  • Cycling: No evidence supports cycling, and no loss of effect over time has been described; no trial protocol used cycling.

Sourcing and Quality

  • Oleuropein standardization: Extracts range from about 1% to 40% oleuropein, and per-serving oleuropein varied about 3-fold (36–100 mg) across products tested by ConsumerLab; labels stating milligrams of oleuropein allow comparison with trial doses.
  • Form: Capsules, tablets, liquid extracts and teas are sold; liquid extract produced higher plasma oleuropein peaks (de Bock et al., 2013) but is very bitter. Tea delivers variable, usually lower amounts.
  • Third-party testing: Products verified by USP (United States Pharmacopeia), NSF International or ConsumerLab for identity, oleuropein content and heavy metals reduce contamination risk; ConsumerLab-approved products passed heavy-metal screening.
  • Branded extracts with trial data: EFLA 943 (Frutarom) and Bonolive (BioActor) underlie most published trials; consumer brands reviewed by ConsumerLab include Comvita, Nature’s Way, NOW, Solaray and Swanson.
  • Leaf quality: Oleuropein content depends on cultivar, season, leaf age and drying method, and extraction solvent changes the polyphenol profile, so two products with equal milligram doses may differ substantially.

Practical Considerations

  • Time to effect: Blood-pressure and lipid changes appeared after 6–8 weeks in trials (Lockyer et al., 2017; Susalit et al., 2011); bone effects were assessed at 12 months (Filip et al., 2015); respiratory benefits accrued over a 9-week season (Somerville et al., 2019).
  • Common pitfalls: Choosing by milligrams of extract rather than oleuropein content; replacing prescribed blood-pressure therapy instead of adding under supervision; expecting antibiotic-like effects from laboratory data; attributing unrelated symptoms to an unproven “die-off” reaction.
  • Regulatory status (US): Sold as a dietary supplement under DSHEA (Dietary Supplement Health and Education Act), under which manufacturers, not the US Food and Drug Administration, evaluate safety and labeling before marketing (FDA).
  • Regulatory status (EU): The European Medicines Agency’s herbal committee recognizes olive leaf only as a traditional herbal medicine for mild water retention in adults (EMA); blood pressure is not an approved indication.
  • Cost and payers: Inexpensive and widely available. Insurers do not reimburse it; generic blood-pressure drugs are similarly cheap, so no systematic payer incentive favoring either was identified, although lack of patent protection limits funding for large independent trials.

Interaction with Foundational Habits

  • Sleep: None direct. No trial has measured sleep outcomes. Morning dosing is typical; in older adults combining it with blood-pressure drugs, light-headedness during night-time rising is a theoretical consideration.
  • Nutrition: Overlapping and potentiating. Extra virgin olive oil supplies related polyphenols. Taken with a small sucrose load, the extract blunted the blood-sugar rise, but not with bread (Kerimi et al., 2019); added to a calorie-restricted diet, it accompanied greater weight loss (Haidari et al., 2021).
  • Exercise: Potentiating at the enzyme level only. With moderate cycling, the extract raised muscle PDH activity and lowered heart rate, but it did not reduce fatigue after moderate or sprint exercise (Lanfranchi et al., 2026, with Nestlé co-authors); no blunting of training adaptation has been reported.
  • Stress management: None demonstrated. A pilot trial in women with anxiety found no effect on anxiety scores (Hernández-Garibay et al., 2026), and no cortisol data exist; any blood-pressure lowering complements rather than replaces stress-reduction practices.

Monitoring Protocol & Defining Success

Baseline testing: Before starting, a week of seated home blood-pressure readings establishes a reference, together with a fasting lipid panel, fasting glucose, HbA1c and kidney function (creatinine with eGFR (estimated glomerular filtration rate, a measure of kidney filtering)). People using the extract for bone health add a DXA (dual-energy X-ray absorptiometry) bone scan if none is recent. Warfarin users record a stable INR.

Ongoing monitoring: Home blood pressure is checked weekly for the first 4 weeks, then monthly. Lipids, glucose and HbA1c are repeated at 8–12 weeks, then every 6–12 months. Kidney function is rechecked every 6–12 months in people with heart or kidney disease or on diuretics. Warfarin users repeat INR 1–2 weeks after starting or stopping. A repeat bone scan is meaningful only after 1–2 years.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Home blood pressure <120/80 mmHg (“normal” per the 2017 ACC/AHA guideline) Expected to change; also a safety check for over-lowering Source: Whelton et al., 2018 (ACC/AHA: American College of Cardiology/American Heart Association). Both are professional and advocacy bodies whose cardiologist members treat high blood pressure, so lower thresholds can widen their patient base; neither has a stake in olive leaf extract. Conventional reference range: <120/80 mmHg. Seated after 5 minutes’ rest, morning, before dosing; average several days
LDL cholesterol <100 mg/dL (“optimal” per NCEP ATP III) Expected to change (possible small decrease) Source: NCEP ATP III, 2002 (NCEP ATP III: National Cholesterol Education Program Adult Treatment Panel III). Conventional reference range: <130 mg/dL on most laboratory reports. Fasting 9–12 hours; pair with triglycerides and HDL (high-density lipoprotein, the carrier that removes cholesterol from arteries)
Triglycerides <150 mg/dL (“normal” per NCEP ATP III) Expected to change (possible small decrease) Source: NCEP ATP III, 2002. Conventional reference range: <150 mg/dL. Fasting required; recent alcohol raises values
Fasting glucose 70–99 mg/dL (standard reference range) Safety check for hypoglycemia with diabetes drugs; possible change Fasting 8 hours, morning draw
HbA1c 4.0–5.6% (standard reference range) Expected to change (diabetes only); safety check with glucose-lowering drugs Reflects about 3 months of glucose; anemia and recent blood loss distort results
Creatinine with eGFR >60 mL/min/1.73 m² (standard reference range) Safety check: severe kidney disease excludes use (EMA) eGFR declines with age; compare with own baseline; relevant with diuretics
Bone mineral density (DXA) No established target; track change from own baseline T-score Expected to change (bone use only) T-score: bone density compared with a healthy young-adult average. Same scanner each time; interval of at least 1–2 years
INR (warfarin users only) No established target for the extract; track change from own stable baseline Safety check for altered warfarin effect Check 1–2 weeks after starting or stopping

Qualitative markers:

  • Dizziness or light-headedness on standing
  • Digestive comfort
  • Frequency and duration of colds
  • Energy and exercise tolerance
  • Joint comfort, if used for knees
  • Menopausal symptoms, if relevant
  • Skin reactions such as hives, a sign of allergy

Emerging Research

  • Training-adaptation trial (recruiting): NCT07729072 (University of Lausanne) gives 60 healthy volunteers 250 mg extract or placebo daily for 21 days of training; primary endpoint maximal aerobic power; completion 2029. A positive result would upgrade the muscle item; a null result would confine it to enzyme signals.
  • Cognitive-function trial (not yet recruiting): NCT07586410 (EPO, an Italian supplement maker) plans 99 adults on 600 mg extract (72 mg oleuropein), extract plus mullein, or placebo; outcomes are two standard cognitive screening tests; completion November 2026. Positive results would add placebo-controlled support to the brain item; null results would weaken it.
  • Diabetes trial (completion date passed): NCT05605704 (University of Monastir; 500 participants; Atherolive 400 mg daily for 3 months; HbA1c and continuous glucose) passed its December 2025 completion date, still lists recruiting, and has no posted results. A positive result would revive the blood-sugar item; a null one would weaken it further.
  • Hypertension trial (completed, no results posted): NCT05636826 (University of Monastir; 500 participants; Atherolive 400 mg daily for 3 months) completed in December 2025 with no results posted. A positive result would reinforce the blood-pressure item; a null result would reduce confidence in it.
  • Independent cardiometabolic replication: The null 2026 pooled analysis (Câmara Rocha Menezes et al., 2026) and the positive 621-patient trial (Lamti et al., 2025) frame the open question: whether blood-pressure and lipid effects survive longer, independently funded trials using 24-hour measurement.
  • Aging-mechanism translation: Mouse evidence that oleuropein activates muscle mitochondrial calcium uptake (Gherardi et al., 2025) and acute human enzyme effects (Lanfranchi et al., 2026) set up chronic trials in older adults; failure to improve strength or endurance would weaken the healthspan rationale.
  • Safety and interaction gap: The only metabolic interaction evidence is a mouse study of liver enzyme induction (Malliou et al., 2021); a human interaction study could confirm or retire this concern, and no long-term safety study exists.

Conclusion

Olive leaf extract is a concentrated, orally administered preparation of olive tree leaves whose main active compound is converted by the body into substances also found in high-quality olive oil. For health-focused adults, its most consistent human signal is a small reduction in blood pressure, seen mainly when readings run above normal, though not in every trial.

Effects on cholesterol, blood fats and blood sugar are inconsistent: some trials report modest improvements, while the most narrowly focused combined analysis finds none. Single trials report shorter colds, steadier bone density after menopause, better menopausal quality of life and better gum healing, but none has been repeated by an independent team. The case for slower aging rests on animal and laboratory work; in older men, a change in a muscle enzyme did not translate into greater strength or endurance.

Reported side effects are uncommon and mild, chiefly stomach upset, with occasional allergic reactions in people sensitive to olive pollen. The main practical considerations are added lowering of blood pressure or blood sugar alongside prescription medicines, and possible effects on bleeding and drug breakdown that rest only on laboratory and animal findings.

The evidence base is small and short-term, and much of it comes from companies that make or sell the extracts tested, behind both favorable and unfavorable findings. The blood-pressure targets used for tracking come from heart-specialist bodies whose members treat high blood pressure but have no stake in the extract. Product strength also varies widely between brands.

Top - Benefits - Risks - Protocol